Evista reduces breast cancer risk

Good news for a change from the NY Times:

"A drug already in widespread use to prevent bone thinning in women
past menopause can also reduce their risk of invasive breast cancer,
researchers reported yesterday.

The drug is raloxifene, sold as Evista, which half a million American
women take for osteoporosis. It is the second drug found to reduce the
risk of breast cancer. The first was tamoxifen, whose brand name is
Nolvadex, which is approved to treat breast cancer and also prevent it
in women at high risk for the disease.

A study sponsored by the National Cancer Institute has found that
raloxifene works as well as tamoxifen in women at high risk for
invasive breast cancer, and it may have fewer side effects. In those
cases, each drug halves the risk.
By DENISE GRADY
Published: April 18, 2006"
http://tinyurl.com/ql6uf
.

Relevant Pages

  • When it comes to Herceptin, some healthy skepticism is, well, quite healthy.
    ... The breast cancer drug trastuzumab (better known by its brand name ... Herceptin) has had more than its share of good press. ... Providing Herceptin to a select group of breast cancer patients would ... the risk of recurrence by half. ...
    (sci.med.diseases.cancer)
  • Re: Evista reduces breast cancer risk
    ... It has also increase my bone density too. ... past menopause can also reduce their risk of invasive breast cancer, ... The drug is raloxifene, sold as Evista, which half a million American ... risk of breast cancer. ...
    (alt.support.arthritis)
  • Panel vote on label change for raloxifene
    ... Cuts Breast-Cancer Risk ... WASHINGTON -- A Food and Drug Administration panel backed a request by ... cuts the risk of getting breast cancer, ... be effective for women considered at high risk for developing breast ...
    (sci.med.cardiology)
  • Re: rastuzumab/Herceptin
    ... The breast cancer drug trastuzumab (better known by its brand name ... Herceptin) has had more than its share of good press. ... Providing Herceptin to a select group of breast cancer patients would ... the risk of recurrence by half. ...
    (sci.med.diseases.cancer)
  • Tamoxifen not licensed in Australia for use as a preventative measure
    ... A US study showing that breast cancer drug Tamoxifen does not appear to ... drug is not used for prevention, ... But for women at the low end of the high risk group, ...
    (sci.med.diseases.cancer)
Loading